BIOMAT Database Logo BIOMAT Database Logo

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. 1998

J S Montaner, and P Reiss, and D Cooper, and S Vella, and M Harris, and B Conway, and M A Wainberg, and D Smith, and P Robinson, and D Hall, and M Myers, and J M Lange
Canadian HIV Trials Network, St Paul's Hospital/University of British Colombia, Vancouver. jmontaner@hivnet.ubc.edu.ca

BACKGROUND Current guidelines recommend that individuals infected with the human immunodeficiency virus type 1 (HIV-1) be treated using combinations of antiretroviral agents to achieve sustained suppression of viral replication as measured by the plasma HIV-1 RNA assay, in the hopes of achieving prolonged remission of the disease. However, until recently, many drug combinations have not led to sustained suppression of HIV-1 RNA. OBJECTIVE To compare the virologic effects of various combinations of nevirapine, didanosine, and zidovudine. METHODS Double-blind, controlled, randomized trial. METHODS University-affiliated ambulatory research clinics in Italy, the Netherlands, Canada and Australia (INCAS). METHODS Antiretroviral therapy-naive adults free of the acquired immunodeficiency syndrome with CD4 cell counts between 0.20 and 0.60x10(9)/L (200-600/microL). METHODS Patients received zidovudine plus nevirapine (plus didanosine placebo), zidovudine plus didanosine (plus nevirapine placebo), or zidovudine plus didanosine plus nevirapine. METHODS Plasma HIV-1 RNA. RESULTS Of the 153 enrolled patients, 151 were evaluable. At week 8, plasma HIV-1 RNA levels had decreased by log 2.18, 1.55, and 0.90 in the triple drug therapy, zidovudine plus didanosine, and zidovudine plus nevirapine groups, respectively (P<.05). The proportions of patients with plasma HIV-1 RNA levels below 20 copies per milliliter at week 52 were 51%, 12%, and 0% in the triple drug therapy, zidovudine plus didanosine, and zidovudine plus nevirapine groups, respectively (P<.001). Viral amplification was attempted in 59 patients at 6 months. Viral isolation was unsuccessful in 19 (79%) of 24, 10 (53%) of 19, and 5 (31%) of 16 patients in the triple drug therapy, zidovudine plus didanosine, and zidovudine plus nevirapine groups, respectively. Among patients from whom virus could be amplified, resistance to nevirapine was found in all 11 patients receiving zidovudine plus nevirapine and in all 5 patients receiving triple drug therapy. Rates of disease progression or death were 23% (11/47), 25% (13/53), and 12% (6/51) for the zidovudine plus nevirapine, zidovudine plus didanosine, and triple drug therapy groups, respectively (P=.08). CONCLUSIONS Triple drug therapy with zidovudine, didanosine, and nevirapine led to a substantially greater and sustained decrease in plasma viral load than the 2-drug regimens studied. Our results also suggest that suppression of viral replication, as demonstrated by a decrease in the plasma HIV-1 RNA load below the level of quantitation of the most sensitive test available, may at least forestall the development of resistance.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human

Related Publications

J S Montaner, and P Reiss, and D Cooper, and S Vella, and M Harris, and B Conway, and M A Wainberg, and D Smith, and P Robinson, and D Hall, and M Myers, and J M Lange
Nevirapine, didanosine, and zidovudine for patients with HIV: the INCAS trial. Italy, Netherlands, Canada, and Australia.
January 1999, JAMA,
J S Montaner, and P Reiss, and D Cooper, and S Vella, and M Harris, and B Conway, and M A Wainberg, and D Smith, and P Robinson, and D Hall, and M Myers, and J M Lange
Nevirapine, didanosine, and zidovudine for patients with HIV: the INCAS trial. Italy, Netherlands, Canada, and Australia.
January 1999, JAMA,
J S Montaner, and P Reiss, and D Cooper, and S Vella, and M Harris, and B Conway, and M A Wainberg, and D Smith, and P Robinson, and D Hall, and M Myers, and J M Lange
Nevirapine, didanosine, and zidovudine for patients with HIV: the INCAS trial. Italy, Netherlands, Canada, and Australia.
January 1999, JAMA,
J S Montaner, and P Reiss, and D Cooper, and S Vella, and M Harris, and B Conway, and M A Wainberg, and D Smith, and P Robinson, and D Hall, and M Myers, and J M Lange
Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. INCAS study team.
November 1999, Journal of acquired immune deficiency syndromes (1999),
J S Montaner, and P Reiss, and D Cooper, and S Vella, and M Harris, and B Conway, and M A Wainberg, and D Smith, and P Robinson, and D Hall, and M Myers, and J M Lange
Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee.
August 1996, Lancet (London, England),
J S Montaner, and P Reiss, and D Cooper, and S Vella, and M Harris, and B Conway, and M A Wainberg, and D Smith, and P Robinson, and D Hall, and M Myers, and J M Lange
Quality of life outcomes of combination zidovudine- didanosine-nevirapine and zidovudine-didanosine for antiretroviral-naive advanced HIV-infected patients.
November 2000, AIDS (London, England),
J S Montaner, and P Reiss, and D Cooper, and S Vella, and M Harris, and B Conway, and M A Wainberg, and D Smith, and P Robinson, and D Hall, and M Myers, and J M Lange
A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
June 2002, Antiviral therapy,
J S Montaner, and P Reiss, and D Cooper, and S Vella, and M Harris, and B Conway, and M A Wainberg, and D Smith, and P Robinson, and D Hall, and M Myers, and J M Lange
A randomized, double-blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001). HIV Netherlands Australia Thailand Research Collaboration.
July 2000, AIDS (London, England),
J S Montaner, and P Reiss, and D Cooper, and S Vella, and M Harris, and B Conway, and M A Wainberg, and D Smith, and P Robinson, and D Hall, and M Myers, and J M Lange
Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
June 1996, Annals of internal medicine,
J S Montaner, and P Reiss, and D Cooper, and S Vella, and M Harris, and B Conway, and M A Wainberg, and D Smith, and P Robinson, and D Hall, and M Myers, and J M Lange
Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. The Bristol-Myers Squibb AI454-010 Study Group.
March 1994, Annals of internal medicine,
Copied contents to your clipboard!